- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Ritholtz Wealth Management Boosts Rigel Pharmaceuticals Holdings
Investment firm increases stake in biotech company by over 900%
Apr. 12, 2026 at 10:05am
Got story updates? Submit your updates here. ›
Ritholtz Wealth Management's major investment in Rigel Pharmaceuticals reflects the firm's confidence in the biotech company's specialized pharmaceutical manufacturing capabilities.South San Francisco TodayRitholtz Wealth Management, a prominent investment management firm, has significantly increased its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a biotechnology company. According to a recent SEC filing, Ritholtz Wealth Management acquired an additional 72,999 shares of Rigel Pharmaceuticals, representing a 961.3% increase in its stake during the fourth quarter.
Why it matters
This substantial investment by Ritholtz Wealth Management, a respected financial institution, suggests the firm sees significant potential in Rigel Pharmaceuticals' future prospects. The biotech sector has been a focus for many investors seeking growth opportunities, and Ritholtz's move highlights their confidence in Rigel's pipeline and market positioning.
The details
Ritholtz Wealth Management now owns a total of 80,593 shares of Rigel Pharmaceuticals, representing approximately 0.44% of the company's outstanding stock. The firm acquired the additional shares during the fourth quarter of the previous year, according to the SEC filing. Rigel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for immune, hematologic, and oncologic diseases.
- Ritholtz Wealth Management increased its Rigel Pharmaceuticals holdings in the fourth quarter of 2025.
The players
Ritholtz Wealth Management
A prominent investment management firm that has significantly increased its stake in Rigel Pharmaceuticals.
Rigel Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for immune, hematologic, and oncologic diseases.
The takeaway
Ritholtz Wealth Management's substantial investment in Rigel Pharmaceuticals suggests the firm sees significant potential in the biotech company's future prospects, highlighting the growing investor interest in the sector and the perceived value of Rigel's pipeline and market positioning.
